News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|February 1, 2008

Balancing the scales

Tinea incognito is a dermatophyte infection that has been altered by use of topical or systemic corticosteroids. It lacks the classic features of a ringworm infection due to corticosteroid suppression of inflammation and altered local immune response.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Safety, tolerability of tenapanor in pediatric IBS-C patients, with Thomas Wallach, MD

Safety, tolerability of tenapanor in pediatric IBS-C patients, with Thomas Wallach, MD

ByThomas Wallach, MD

November 7th 2025

Odevixibat demonstrates sustained pruritus and bile acid improvements in FIC1 deficiency | Image Credit: © mi_viri - stock.adobe.com.

Odevixibat demonstrates sustained pruritus and bile acid improvements in FIC1 deficiency

ByJoshua Fitch, Senior Editor

November 7th 2025

Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C

Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C

ByJulie Khlevner, MD, AGAF

November 7th 2025

Linaclotide demonstrates positive long-term safety | Image Credit: © eddows - stock.adobe.com.

Linaclotide demonstrates positive long-term safety

ByJoshua Fitch, Senior Editor

November 6th 2025

Doxycycline for post-exposure prevention of Lyme disease in young children | Contemporary Pediatrics

Wesley Kufel, PharmD, discusses doxycycline for post-exposure prevention of Lyme disease in young children

ByWesley Kufel, PharmD, BCPS, BCIDP, FCCP, FIDSA

November 6th 2025

Latest CME

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Jay B. Wish, MD

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

© 2025 MJH Life Sciences^®

All rights reserved.